KR20180077927A - Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof - Google Patents
Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof Download PDFInfo
- Publication number
- KR20180077927A KR20180077927A KR1020160182816A KR20160182816A KR20180077927A KR 20180077927 A KR20180077927 A KR 20180077927A KR 1020160182816 A KR1020160182816 A KR 1020160182816A KR 20160182816 A KR20160182816 A KR 20160182816A KR 20180077927 A KR20180077927 A KR 20180077927A
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- extract
- peony
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000002087 whitening effect Effects 0.000 title claims abstract description 35
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 15
- 244000236658 Paeonia lactiflora Species 0.000 title description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 title description 3
- 230000003064 anti-oxidating effect Effects 0.000 title description 2
- 241000736199 Paeonia Species 0.000 claims abstract description 96
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 95
- 239000002537 cosmetic Substances 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 23
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 230000036541 health Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 12
- 244000105624 Arachis hypogaea Species 0.000 claims description 12
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 12
- 235000018262 Arachis monticola Nutrition 0.000 claims description 12
- 235000020232 peanut Nutrition 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 102000003425 Tyrosinase Human genes 0.000 abstract description 19
- 108060008724 Tyrosinase Proteins 0.000 abstract description 19
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 abstract description 10
- 239000000654 additive Substances 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 7
- 230000007760 free radical scavenging Effects 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000954 anitussive effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- -1 glycerol aliphatic ester Chemical class 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 description 8
- 229960000271 arbutin Drugs 0.000 description 8
- 239000002034 butanolic fraction Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 244000144730 Amygdalus persica Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000002036 chloroform fraction Substances 0.000 description 6
- 239000002038 ethyl acetate fraction Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000061 acid fraction Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 241000124501 Paeonia obovata var. japonica Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002519 antifouling agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 108091049293 miR-253 stem-loop Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 미백, 항산화 또는 항균용 조성물에 관한 것이다. 본 발명의 작약 추출물 또는 이의 분획물은 티로시나제 활성 억제 효과가 우수하며, DPPH, ABTS 자유 라디칼 소거능 등이 우수하고, E. coli , S. aureus 등을 포함하는 세균에 대한 항균 활성 효과를 가지고 있다. 상기와 같은 미백, 항산화 및 항균 활성을 바탕으로 본 발명의 조성물은 미백 또는 노화 방지용 화장료 조성물로서 활용될 수 있고, 더 나아가 미백, 항산화 또는 항균과 관련된 건강기능식품, 항균용 조성물, 피부 외용제, 식품 첨가제 등으로 유용하게 활용될 수 있다.The present invention relates to a composition for whitening, antioxidant or antimicrobial activity comprising an extract of Peony root or a fraction thereof as an active ingredient. The peony extract of the present invention or its fraction has an excellent antitussive effect against tyrosinase activity, excellent DPPH and ABTS free radical scavenging activity, and an antimicrobial activity against bacteria including E. coli and S. aureus . Based on the whitening, antioxidant, and antibacterial activity as described above, the composition of the present invention can be utilized as a cosmetic composition for whitening or antiaging, and furthermore can be used as a cosmetic composition for skin whitening, antioxidant or antibacterial activity, Additives and the like.
Description
본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 미백, 항산화 또는 항균용 조성물에 관한 것이다.The present invention relates to a composition for whitening, antioxidant or antimicrobial activity comprising an extract of Peony root or a fraction thereof as an active ingredient.
사람의 피부는 노화가 진행됨에 따라 내적으로 신진대사를 조절하는 각종 호르몬의 분비가 감소하고 면역세포 및 피부세포의 기능과 활성이 저하되어 생체에 필요한 면역단백질 및 생체구성 단백질들의 생합성이 줄어들게되어 생기는 내인성노화(intrinsic aging)가 일어나며, 외적으로는 오존층 파괴로 인하여 태양광선 중 지표에 도달하는 자외선의 함량이 증가하게 되고 환경오염이 더욱 심화됨에 따라 자유 라디칼 및 활성 유해 산소 등이 증가함으로써, 피부의 두께가 감소하고, 주름이 증가되고, 탄력이 감소될 뿐 아니라 피부 혈색도 칙칙하게 안 좋아지게 되고, 피부트러블이 자주 발생하며, 기미와 주근깨 및 검버섯 또한 증가하는 등 여러 가지 변화를 일으키게 된다.As the aging of human skin progresses, the secretion of various hormones that regulate metabolism is reduced, and the function and activity of immune cells and skin cells are lowered. As a result, the biosynthesis of immune proteins and biocompatible proteins necessary for the living body is reduced, Intrinsic aging occurs, and as a result, the content of ultraviolet rays reaching the surface of the sunlight increases due to destruction of the ozone layer, and as the environmental pollution is further intensified, free radicals and active noxious oxygen are increased, Not only the thickness is reduced, the wrinkles are increased, the elasticity is reduced, the skin color is also dullly improved, skin troubles are frequent, and spots, freckles and black spots are also increased.
화장품 분야는 신기술이 융합될 수 있는 대표적인 분야로서 21세기 화장품 업계의 화두가 기능성 화장품이라고 해도 과언이 아닐 정도로 기능성 화장품에 대한 관심과 소비는 시간이 지남에 따라 증가하는 추세이다. 한국보건산업진흥원의 2013년 화장품 산업 분석 보고서에 따르면 이러한 화장품 산업은 고성장이 전망되는 유망산업으로 각광받고 있으며, 아름다움에 대한 추구 경향, 여성의 경제활동 인구증가, 남성과 유아 등 소비계층의 확대에 힘입어 글로벌 경제 위기에도 불구하고 2013년 세계 화장품 시장 규모 2,495억 달러로 전년대비 3.9% 증가했고 향후에도 지속되어 2016년 3,089억 달러로 꾸준한 증가세를 보일 것으로 전망된다고 밝힌 바가 있다. 그 중에서도 미백, 노화방지, 주름개선, 자외선 차단 등 다양한 기능성을 가지는 기능성 화장품에 대한 관심이 높다.The field of cosmetics is a typical field where new technology can be converged. It is no exaggeration to say that the topic of cosmetics in the 21st century is functional cosmetics. Interest and consumption of functional cosmetics are increasing with time. According to the report of the Korea Health Industry Promotion Agency (KHIDI) in 2013, the cosmetics industry is seen as a promising industry with high growth potential. The trend is to pursue beauty, increase the economically active population of women, Despite the global economic crisis, the global cosmetics market is forecast to grow by 3.9% YoY to US $ 249.5bn in 2013 and continue to grow steadily to US $ 308.9bn in 2016. Among them, there is a high interest in functional cosmetics having various functions such as whitening, anti-aging, wrinkle improvement, and ultraviolet shielding.
특히, 최근에는 화장품 성분의 유전자 변형이나 환경 호르몬으로 인한 문제점이 대두되면서 장기적으로 인체에 유해하지 않고 안전하게 사용할 수 있는 천연물질 추출물을 주성분으로 하는 기능성 화장품에 기대가 높아지고 있다. 작약(芍藥, Jakyak, Paeoniae radix)은 참작약 및 동속 식물의 뿌리로서 매우 중요한 생약 중의 하나이다. 잎은 어긋나고, 잎자루는 길며, 2회 삼출 겹잎으로 작은 잎은 타원형이며, 톱니는 없다. 꽃은 줄기 끝에 한 개씩나며, 5~6월에 흰 꽃이 핀다. 생약으로는 뿌리를 말린 것이며, 생지는 산의 나무 그늘에서 자란다. 우리나라 전국에 분포되어 있으며, 한방에서는 3월과 8월에 땅속줄기를 채취하여 햇볕에 말려 치조(治操), 양혈제(凉血劑), 보혈(補血), 익비(益脾), 지통(止痛)에 사용한다. 한방에서는 수렴완화(斂緩和), 진경(鎭痙), 진통제(痛)로서 사용되어 왔으며, 계지가화균약탕 등으로 사용되어 왔다. 과실은 골돌과로서 1~3개이고, 뿔 모양으로 홍색의 성숙하지 않은 종자와 흑색의 성숙한 종자가 노출된다. 번식은 분근을 하거나 종자를 이용한다. 약용으로 쓰이는 작약은 미나리아재비과(Ranuculaceae) 작약속(Paeonia)에 속하는 약용작물로서 초본인 작약과 목본인 모란으로 구분된다. 국내에서 재배되는 작약은 식물 분류 면에서 적작약(Paeonia lactiflora Pall), 백작약(Paeonia obovata Max.) 및 산작약(Paeonia japonica Miyabe et Takeda)으로 구분된다.In particular, recently, problems arise due to genetic modification of cosmetic ingredients and environmental hormones, so that functional cosmetics based on extracts of natural substances that can be safely used without being harmful to the human body in the long term are increasingly expected. Peony (藥药, Jakyak, Paeoniae radix) is one of the most important medicinal herbs as a root of the medicinal herb and its plants. Leaves are alternate phyllotaxis, petiole is long, 2 times exudate leaf, small leaf is elliptical, and there is no sawtooth. Flowers bloom one at the end of the stem and bloom in May-June. Herbal medicine is dried root, and the plant grows in the shade of a mountain tree. It is distributed all over Korea. In one branch, it is collected in March and August, and it is dried in the sun to produce a mixture of algae, blood 补血 補, blood 补血, Pain). In the oriental medicine, it has been used as convergence relaxation, jinbyeong, and analgesic (pain), and the stamens have been used as bacillus. Fruits are 1 ~ 3 corolla, and horny, red mature seeds and black mature seeds are exposed. The breeding is done in the form of a minus or seed. The medicinal peony is a medicinal plant belonging to the Ranuculaceae Paeonia, which is divided into herbaceous peony and tree-like peony. Paeonia lactiflora Pall, Paeonia obovata Max., And Paeonia japonica Miyabe et Takeda are classified as phytophagous cultivated in Korea.
본 발명자들은 제품 안정성이 우수하고 피부에 대한 부작용 없이 안전하게 사용될 수 있으며 항균, 항산화 및 미백 효과가 우수한 유효물질을 천연재료를 대상으로 개발하고자 노력하였다. 그 결과, 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 조성물이 현저한 항산화 또는 미백 효과를 가짐을 확인하고, 본 발명을 완성하였다.The present inventors have sought to develop an effective substance having excellent antibacterial, antioxidant and whitening effect, which can be safely used without adverse effects on skin, and which has excellent product stability, as a natural material. As a result, it was confirmed that the composition containing the peony extract or fraction thereof as an active ingredient had a remarkable antioxidant or whitening effect, and thus the present invention was completed.
본 발명의 목적은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항산화, 항균 또는 미백용 조성물을 제공하는 것이다.An object of the present invention is to provide a composition for antioxidant, antibacterial or whitening comprising an extract of Peony root or a fraction thereof as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 미백 또는 노화 방지용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for skin whitening or anti-aging comprising peony extract or fractions thereof as an active ingredient.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 상태 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for improving skin condition comprising an extract of peony root extract or a fraction thereof as an active ingredient.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항균용 조성물을 제공한다.In addition, the present invention provides an antimicrobial composition comprising a peony root extract or a fraction thereof as an active ingredient.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항균용 피부 외용제 조성물을 제공한다.The present invention also provides a composition for external application for skin for antimicrobial use comprising an extract of Peony root or a fraction thereof as an active ingredient.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항균용 식품 첨가제를 제공한다.The present invention also provides an antimicrobial food additive comprising an extract of Peony root or a fraction thereof as an active ingredient.
본 발명의 작약 추출물 또는 이의 분획물은 티로시나제 활성 억제 효과가 우수하며, DPPH, ABTS 자유 라디칼 소거능 등이 우수하고, E.coli, S.aureus 등을 포함하는 세균에 대한 항균 활성 효과를 가지고 있다. 상기와 같은 미백, 항산화 및 항균 활성을 바탕으로 본 발명의 조성물은 미백 또는 노화 방지용 화장료 조성물로서 활용될 수 있고, 더 나아가 미백, 항산화 또는 항균과 관련된 건강기능식품, 항균용 조성물, 피부 외용제, 식품 첨가제 등으로 유용하게 활용될 수 있다.The peony extract of the present invention or its fraction has an excellent antitussive effect against tyrosinase activity, excellent DPPH and ABTS free radical scavenging ability, and has an antimicrobial activity effect against bacteria including E. coli and S. aureus . Based on the whitening, antioxidant, and antibacterial activity as described above, the composition of the present invention can be utilized as a cosmetic composition for whitening or antiaging, and furthermore can be used as a cosmetic composition for skin whitening, antioxidant or antibacterial activity, Additives and the like.
도 1은 본 발명에 따른 작약 추출물 및 이의 분획물의 추출 및 분획 과정을 도식화한 도식도를 나타내는 도이다.
도 2은 대조군인 알부틴의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인한 결과를 나타내는 도이다.
도 3은 작약 클로로포름 분획물의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인한 결과를 나타내는 도이다.
도 4는 작약 에틸 아세트산 분획물의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인한 결과를 나타내는 도이다.
도 5는 작약 부탄올 분획물의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인한 결과를 나타내는 도이다.
도 6은 작약 물 분획물의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인한 결과를 나타내는 도이다.
도 7은 MTT 분석을 통해 작약 에틸 아세트산 분획물의 세포 독성을 확인한 결과를 나타내는 도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram illustrating the extraction and fractionation process of the peony root extract and fractions thereof according to the present invention. FIG.
FIG. 2 is a graph showing the result of confirming the inhibitory effect of tyrosinase activity to confirm the whitening effect of arbutin, which is a control group.
FIG. 3 is a graph showing the result of confirming the inhibitory effect of tyrosinase activity in order to confirm the whitening effect of the fragrant chloroform fraction.
4 is a graph showing the results of confirming the inhibitory effect of tyrosinase activity in order to confirm the whitening effect of the ethyl acetate fraction of Peony root.
FIG. 5 is a graph showing the results of confirming the effect of inhibiting tyrosinase activity in order to confirm the whitening effect of the butanol fraction of Peony root.
FIG. 6 is a graph showing the result of confirming the inhibitory effect of tyrosinase activity to confirm the whitening effect of the peony root fraction. FIG.
FIG. 7 is a graph showing the results of confirming the cytotoxicity of the fractions of ethyl acetic acid peanut by MTT analysis. FIG.
본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항산화, 항균 또는 미백용 조성물을 제공한다.The present invention provides an antioxidant, antibacterial or whitening composition comprising an extract of Peony root or a fraction thereof as an active ingredient.
이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 미백 또는 노화 방지용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for skin whitening or antiaging treatment comprising an extract of peony root extract or a fraction thereof as an active ingredient.
본 발명에 있어서, 상기 작약 추출물은 줄기, 잎, 뿌리 추출물인 것을 특징으로 하며, 바람직하게는 줄기 추출물인 것을 특징으로 하나, 이에 제한되는 것은 아니다.In the present invention, the peony root extract is a stem, leaf or root extract, preferably a stem extract, but is not limited thereto.
본 발명에 있어서, 상기 작약 추출물은 당업계에 공지된 추출, 분리 및 분획하는 방법을 사용하여 천연으로부터 추출, 분리 및 분획하여 수득한 것을 사용할 수 있다. 본 발명에서 정의된 "추출물"은 적절한 용매를 이용하여 작약 추출물로부터 추출 처리에 의해 얻어지는 것이며, 예를 들어 작약의 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함하며, 그 중에서도 극성용매 가용 추출물인 것이 바람직하다.In the present invention, the peony root extract may be obtained by extracting, isolating and fractionating the peony root using the extraction, separation and fractionation methods known in the art. The "extract" as defined in the present invention is obtained by extraction treatment from a peony root extract using an appropriate solvent and includes, for example, a crude extract of Peony root, a polar solvent extract or a nonpolar solvent soluble extract, Soluble extract is preferable.
본 발명에 있어서, 상기 작약 추출물은 다양한 추출 용매와 추출 방법에 따라 추출될 수 있으며, 작약 추출물으로부터 추출물을 추출하기 위한 적절한 용매로는 물 또는 유기용매, 예를 들어 상기 용매로는 물, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등의 C1-C4 알코올 또는 이의 혼합용매를 사용할 수 있다. 바람직하게는 본 발명 추출물의 추출 용매로 에탄올을 사용할 수 있으며, 보다 바람직하게는 70 내지 90% 에탄올을 사용할 수 있고, 가장 바람직하게는 80% 에탄올을 사용할 수 있으나 이에 제한되는 것은 아니다. 80% 에탄올을 사용하여 작약 추출물을 제조하는 경우 작약 추출물 내 지용성 및 수용성 활성성분이 모두 충분히 녹아들 수 있고, 이에 항균, 항산화 및 미백 활성에 최적 활성을 나타내는 유효성분의 조합을 포함하는 추출물을 제조할 수 있다.In the present invention, the peony root extract may be extracted according to various extraction solvents and extraction methods. Examples of suitable solvents for extracting peony root extract include water or an organic solvent such as water, methanol C 1 -C 4 alcohols such as methanol, ethanol, propanol, isopropanol, butanol and the like or a mixed solvent thereof may be used. Preferably, ethanol can be used as an extraction solvent for the extract of the present invention, more preferably 70 to 90% ethanol, and most preferably 80% ethanol can be used, but the present invention is not limited thereto. When preparing a peony root extract using 80% ethanol, an extract comprising a combination of active ingredients which can sufficiently dissolve all of the fat soluble and water soluble active ingredients in the peony root extract and exhibit optimal activity for antibacterial, antioxidative and whitening activity can do.
상기 추출 온도는 상온인 것이 바람직하며, 보다 바람직하게는 20 내지 100℃이나, 이에 제한되지 않는다. 또한 추출방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법이 사용될 수 있다.The extraction temperature is preferably room temperature, more preferably 20 to 100 ° C, but is not limited thereto. Examples of the extraction method include hot water extraction, cold extraction, reflux cooling, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression.
상기와 같이 물 또는 유기용매를 이용하여 추출물을 얻은 이후에는 당업계에서 알려진 통상의 방법으로 상온에서 냉침, 가열 및 여과하여 액상물을 얻을 수 있으며, 또는 추가로 용매를 증발, 분무건조 또는 동결건조할 수도 있다.After the extract is obtained using water or an organic solvent as described above, a liquid material can be obtained by freezing, heating and filtering at room temperature by a conventional method known in the art, or a liquid material can be obtained by further evaporating, spray drying or freeze- You may.
본 발명에 있어서, 상기 제조한 작약 추출물은 추가적으로 증류한 후 분획하여 얻을 수 있으며, 구체적으로는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획으로도 얻을 수 있으며, 바람직하게는 박층크로마토그래피를 이용하여 분획할 수 있으나 이에 본 발명이 제한되는 것은 아니고, 적절한 용매를 이용하여 추가 분획물을 얻을 수 있는 방법이라면 어느것이든지 이용할 수 있다.In the present invention, the peony extract can be obtained by further distillation and fractionation. Specifically, it can be obtained by silica gel column chromatography, thin layer chromatography, high performance liquid chromatography performance liquid chromatography, and the like. The fraction may be further fractionated using thin layer chromatography, but the present invention is not limited thereto, and the fraction may be fractionated using an appropriate solvent Any method of obtaining additional fractions can be used.
본 발명에 있어서, 상기 분획물을 얻기 위해 사용하는 용매는 클로로포름, 에틸 아세트산, 부탄올 및 물로 이루어진 군으로부터 선택된 어느 하나 이상일 수 있으며, 바람직하게는 클로로포름, 에틸 아세트산, 부탄올을 사용할 수 있으며, 보다 바람직하게는 에틸 아세트산을 사용할 수 있으나 이에 제한되는 것은 아니다.In the present invention, the solvent used for obtaining the fractions may be any one or more selected from the group consisting of chloroform, ethyl acetic acid, butanol, and water. Preferably, chloroform, ethyl acetic acid, and butanol may be used. Ethyl acetic acid may be used, but is not limited thereto.
본 발명에 있어서, 상기 작약 추출물 또는 이의 분획물은 전체 화장료 조성물에 대해 0.001 내지 60 중량%로 포함되는 것을 특징으로 하며, 0.001 미만의 중량%를 가지는 경우 목적하는 효과의 달성이 어려울 수 있으며, 60을 초과하는 중량%를 가지는 경우 세포독성과 제품제조시 제형 형성의 어려움이 있을 수 있다.In the present invention, the peony extract or the fraction thereof is contained in an amount of 0.001 to 60% by weight with respect to the whole cosmetic composition. When the peony extract has a weight percentage of less than 0.001, it may be difficult to achieve the desired effect. If it has an excess weight percentage, it may be cytotoxic and difficult to formulate the formulations in the manufacture of the product.
본 발명에 있어서, 상기 화장료 조성물은 피부에 손상을 주는 근본적인 원인인 노화방지 또는 미백 효과를 가지며, 상기 '미백'은 피부를 하얗게 하는 것을 말한다.In the present invention, the cosmetic composition has anti-aging or whitening effect as a fundamental cause of damaging the skin, and the 'whitening' means whitening the skin.
멜라닌은 색소 세포 내에 존재하는 티로시나제(tyrosinase)의 작용에 의해 티로신으로부터 복잡한 과정을 거쳐 생성된다. 생성된 멜라닌은 피부 세포에 전달되고, 표피 박리와 함께 멜라닌이 상실되어 소멸되는 순환 작용을 보인다. 즉, 피부가 자외선에 노출되면 티로시나제가 활성화되는데, 상기 티로시나제가 피부조직에 존재하는 티로신에 작용하여 도파(DOPA) 및 도파퀴논을 생성시키는 산화 과정을 유도하고, 이로 인해 피부 색소 세포인 멜라노사이트 내의 멜라노좀에서 멜라닌이 합성되며, 합성된 멜라닌은 피부의 각질 형성 세포인 케라티노사이트로 전달되고, 각질화 과정에 의해 피부 표면에 도달하여 자외선으로부터 피부를 보호하게 된다. 그러나, 멜라닌이 국소적으로 과도하게 합성되거나, 피부 병변 및 노화에 따라 피부의 생리 기능이 떨어지게 되면, 멜라닌이 피부 표면에 침착되어 기미, 주근깨 등의 다양한 색소 침착을 유발하게 되는데, 본 발명의 조성물은 티로시나제의 활성을 억제하여 피부 색소 세포인 멜라노사이트 내의 멜라노좀으로부터 멜라닌 합성이 억제되는 기작을 억제하여 미백 효과를 가지는 것을 특징으로 하며, 이에 본 발명이 제한되는 것은 아니다.Melanin is produced by a complex process from tyrosine by the action of tyrosinase present in the pigment cells. The resulting melanin is transferred to the skin cells, and melanin is lost with epidermal detachment, and the circulating action appears to disappear. That is, when the skin is exposed to ultraviolet rays, tyrosinase is activated. The tyrosinase acts on tyrosine present in the skin tissue to induce an oxidation process of generating dopa (DOPA) and dopaquinone. As a result, Melanin is synthesized in melanoma, and synthesized melanin is transferred to keratinocyte which is keratinocyte of skin and reaches skin surface by keratinization process to protect skin from ultraviolet rays. However, when the melanin is locally over-synthesized or the skin physiological functions are deteriorated due to skin lesions and aging, melanin is deposited on the skin surface and causes various pigment deposits such as spots and freckles. Is characterized by inhibiting the activity of tyrosinase and inhibiting the mechanism by which melanogenesis is suppressed from melanosomes in melanocytes, which are skin pigment cells, to have a whitening effect, and thus the present invention is not limited thereto.
본 발명에 있어서 상기 화장료 조성물이 가지는 노화방지는 항산화 효과로부터 얻어지는 효과로서 노화방지 외에도 산화 상태를 억제 또는 제거하여 예방 또는 치료할 수 있는 다양한 질환, 질병 또는 이상 상태에 적용될 수 있다. 본 발명의 조성물에 의해 예방 또는 치료될 수 있는 항산화 관련 질환은, 아테롬성 동맥경화증, 관상동맥질환, 심장동맥 재협착, 재관류 손상, 파키슨병 또는 알츠하이머 질환과 같은 신경변성 질환, 뇌졸중, 암, 노화, 심혈관 질환, 골다공증, 중추신경계 장애, 말초혈관 질환 및 호흡곤란을 포함하나, 이에 한정되는 것은 아니다.In the present invention, the anti-aging properties of the cosmetic composition of the present invention can be applied to various diseases, diseases or abnormal conditions which can be prevented or treated by inhibiting or eliminating oxidation states as well as anti-aging effects obtained from antioxidative effects. Antioxidant related diseases that can be prevented or treated by the composition of the present invention include, but are not limited to, atherosclerosis, coronary artery disease, coronary artery restenosis, reperfusion injury, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, stroke, But are not limited to, cardiovascular disease, osteoporosis, central nervous system disorders, peripheral vascular disease, and dyspnea.
많은 질환 상태와 자유라디칼 손상과의 상관관계는 널리 입증되어 있으며 효소, 이온채널, 구조 단백질 및 막지질을 포함하는 많은 세포 구성성분이 반응성 자유 라디칼 종에 대한 잠재적인 표적물이다(Rice-Evans C, Mol Aspects of Med 13(1):1-111(1992)). 상기 잠재적인 표적물과 자유 라디칼의 반응은 특정범위의 세포기능을 손상시켜 병리학적 변화를 유발하여 궁극적으로 세포를 사멸시킨다. 또한, 생리학적인 산화에 의해 다양한 질병이 야기되는 것은, 미국 특허 제 5750351; 5773209; 5773231 및 5846959호에 개시되어 있다.The association of many disease states with free radical damage has been well established and many cellular constituents including enzymes, ion channels, structural proteins and membrane lipids are potential targets for reactive free radical species (Rice-Evans C , Mol Aspects of Med 13 (1): 1-111 (1992)). The reaction of these potential targets with free radicals impairs a certain range of cellular function, causing pathological changes and ultimately killing the cells. In addition, various diseases caused by physiological oxidation are described in U.S. Patent No. 5750351; 5773209; 5773231 and 5846959.
본 발명에 있어서 화장료 조성물은 상기 작약 추출물 또는 이의 분획물과 함께 피부 미백 또는 노화방지 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.In the present invention, the cosmetic composition may further contain at least one known active ingredient having skin whitening or anti-aging effect together with the above dried apricot extract or its fraction.
본 발명에 있어서 화장료 조성물에 포함되는 성분은 유효 성분으로서의 작약 추출물 또는 이의 분획물 외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다. 또한, 상기 화장료 조성물은 그 효과를 증진시키기 위하여 피부 흡수 촉진 물질을 추가로 포함할 수 있다.In the present invention, the components contained in the cosmetic composition include components commonly used in cosmetic compositions in addition to the peony extracts or fractions thereof as an active ingredient, and include conventional components such as antioxidants, stabilizers, solubilizers, vitamins, Phosphorous additive, and carrier. In addition, the cosmetic composition may further include a skin absorption promoting substance to improve its effect.
본 발명에 있어서 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.In the present invention, the cosmetic composition may be prepared in any form conventionally produced in the art, for example, a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, But are not limited to, cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명에 있어서 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition in the present invention is a paste, a cream or a gel, an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.
본 발명에 있어서 화장료 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the present invention, when the cosmetic formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, , Propane / butane or dimethyl ether.
본 발명에 있어서 화장료 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the present invention, when the cosmetic preparation is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명에 있어서 화장료 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에 탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.In the present invention, when the cosmetic formulation is an interface-active agent-containing cleansing, the carrier component is selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 상태 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for improving skin condition comprising an extract of peony root extract or a fraction thereof as an active ingredient.
상기 피부 상태 개선은 피부톤(tone), 피부 주름, 피부탄력성 및 피부결 등을 포함하는 피부 건강과 아름다움의 상태를 더 나은 상태가 되도록 하는 것으로, 구체적으로 피부 상태 개선용은 미백 또는 항산화용인 것을 특징으로 하나, 이에 제한되는 것은 아니다.The improvement of the skin condition makes the condition of the skin health and beauty including the skin tone, wrinkles of the skin, elasticity of the skin and skin texture better, and specifically, it is for whitening or antioxidation for improving the skin condition But is not limited thereto.
본 발명에 있어서 건강기능식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병 방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품으로, 장기적으로 복용하였을 때 인체에 무해하여야 한다.In the present invention, the health functional food refers to a food group imparted with added value to function or express the function of the food by physical, biochemical or biotechnological techniques, or to control the bio-defense rhythm of the food composition, And restoration of the body to control the function of the body is designed to fully express the body, long-term consumption should be harmless to human body.
본 발명에 있어서, 건강기능식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강기능식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.In the present invention, the health functional food may include food-acceptable food supplementary additives, and may further include appropriate carriers, excipients and diluents conventionally used in the production of health functional foods.
본 발명의 건강기능식품 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 조성물은 원료에 대하여 15중량 % 이하, 바람직하게는 10 중량 % 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the composition may be added as it is, or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 건강기능식품의 예로는 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병 방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계된 식품을 모두 포함한다.There is no particular limitation on the kind of the health functional food. Examples of health functional foods to which the above substances can be added include dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes. And foodstuffs designed to fully express in vivo the function of controlling the body in terms of regulation of bio-defense rhythm of food composition, prevention and recovery of disease, and the like.
상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 식품 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명은 작약 추출물 또는 이의 분획물을 유효성분으로 포함하는 항균용 조성물을 제공한다.In addition, the present invention provides an antimicrobial composition comprising a peony root extract or a fraction thereof as an active ingredient.
본 발명에 있어서 '항균' 또는 '항균활성'이란, 세균이나 곰팡이와 같은 미생물에 대해 저항하는 성질을 의미하며, 보다 상세하게는 항생물질 등이 세균의 성장 또는 증식을 억제하는 특성을 의미한다.In the present invention, 'antimicrobial' or 'antimicrobial activity' refers to a property of resisting microorganisms such as bacteria or fungi. More specifically, antimicrobial activity means a property of inhibiting growth or proliferation of bacteria.
본 발명에 있어서 '항균용 조성물'은 세균이나 곰팡이와 같은 미생물의 생육을 저해하는 활성을 가진 조성물로서, 항균 효과가 요구되는 다양한 분야에 사용되는 모든 형태가 포함될 수 있으며, 예를 들어, 의약품, 피부 외용제, 식품 첨가제 또는 사료 첨가제 등의 형태일 수 있다. 구체적으로, 의약에 있어서는 항생제나 오염방지제와 같은 목적으로, 식품에 있어서는 방부나 항균목적으로, 화장품이나 생활용품에 있어서는 항여드름용 등 미생물과 직접 연관된 제품에 사용될 수 있으며, 이러한 목적으로만 한정되는 것은 아니다.In the present invention, the 'antimicrobial composition' is a composition having an activity of inhibiting the growth of microorganisms such as bacteria or fungi, and may include all forms used in various fields requiring an antimicrobial effect. Examples thereof include medicines, A skin external preparation, a food additive or a feed additive. Specifically, it can be used for medicines such as antibiotics and antifouling agents, in foodstuffs for preservation or antibacterial purposes, in cosmetics and household goods, for anti-acne products, and in products directly related to microorganisms. It is not.
상기 본 발명 조성물의 항균 효과는 그람음성균 및 그람양성균을 가리지 않고 일반적인 모든 종류의 세균에 나타나는 효과이며, 바람직하게는 대표적인 그람음성균인 대장균(E. coli) 및 녹농균(P.aeruginosa), 대표적인 그람양성균인 황색포도상구균(S. aureus) 및 표피포도구균(S.epidermidis)에 대한 항균 효과이나, 이에 본 발명이 제한되는 것은 아니다. The antimicrobial effect of the composition of the invention is the effect that appears in common in all kinds of bacteria, without the cover-positive gram-negative and gram, preferably a representative of Gram-negative bacteria Escherichia coli (E. coli) and Pseudomonas aeruginosa (P.aeruginosa), Gram-positive bacteria representative But not limited to, S. aureus and S. epidermidis .
상기에 언급한 바와 같이 본 발명을 의약으로 사용하는 경우 본 발명의 조성물은 약학적으로 허용 가능한 첨가제를 더 포함할 수 있으며, 이때 약학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당 등이 사용될 수 있다. 본 발명에 따른 약학적으로 허용 가능한 첨가제는 상기 조성물에 대해 0.1 내지 90 중량부 포함되는 것이 바람직하나 이에 한정되는 것은 아니다.As described above, when the present invention is used as a medicament, the composition of the present invention may further comprise pharmaceutically acceptable additives. Examples of the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, Lactose, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, sugar, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropylcellulose, opaques, starch glycolate sodium, carnauba wax, synthetic Aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, and white sugar may be used. The pharmaceutically acceptable additives according to the present invention are preferably included in the composition in an amount of 0.1 to 90 parts by weight, but not limited thereto.
본 발명에 있어서 상기 조성물은 실제 임상 투여시에 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제할 수 있으며, 당해 기술 분야에 알려진 적합한 제제는 문헌 (Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 이용하는 것이 바람직하다. 상기 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유 등이 있다.In the present invention, the composition may be administered orally or parenterally in various clinical formulations. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, (Remington ' s Pharmaceutical Science, recently published by Mack Publishing Company, Easton PA) is preferably used. Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
상기 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(Calcium carbonate), 수크로스 (Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 또한, 상기 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. The solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like May be included.
상기 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 상기 비경구투여는 피부 외용 또는 복강 내 주사, 직장 내 주사, 피하주사, 정맥주사, 근육 내 주사 또는 흉부 내 주사 주입방식을 사용하여 이루어질 수 있다.The preparation for parenteral administration includes sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used. The parenteral administration can be carried out using an external or intraperitoneal injection, intramuscular injection, subcutaneous injection, intravenous injection, intramuscular injection or intra-thoracic injection.
상기 본 발명의 조성물은 약학적으로 유효한 양으로 투여될 수 있다.The composition of the present invention may be administered in a pharmaceutically effective amount.
용어 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 감염된 바이러스 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 100mg/kg으로, 바람직하게는 0.001 내지 100mg/kg으로 투여하는 것이 좋다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dosage level will vary depending on the species and severity, age, sex, Activity, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100 mg / kg per day, preferably 0.001 to 100 mg / kg per day. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
본 발명에 있어서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used in the present invention means providing a certain composition of the present invention to a subject in any suitable manner.
본 발명에 있어서 항균용 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.In the present invention, the antimicrobial composition can be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 항균용 조성물은 항균을 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The antimicrobial composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for antibacterial activity.
상술한 본 발명의 조성물에 대한 설명은 중복된 내용의 기재에 의한 과도한 복잡성을 피하기 위하여 그 기재를 생략하며, 본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 의미를 갖는 것이다.The above description of the composition of the present invention is omitted in order to avoid excessive complexity due to the overlapping description, and terms not otherwise defined in the present specification mean the terms commonly used in the technical field of the present invention .
이하 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 제제예를 제시한다. 그러나 하기 실시예 및 제제예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 이에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments and examples of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples and preparation examples are provided only for the purpose of easier understanding of the present invention, and thus the content of the present invention is not limited thereto.
실시예Example 1. 작약 추출물 및 이의 1. Peony extract and its 분획물의Fraction 제조 Produce
1-1. 작약 추출물의 제조1-1. Manufacture of peony extracts
본 실험에 사용한 작약(Paeonia lactiflora Pall.)은 경남 산청군 소재의 국산 야생, 토종 약초를 전문으로 하는 지리산 약초골에서 구입하여 사용하였다. 음건되어 있는 작약 5kg에 80%(v/v) 에탄올(Ethanol)을 가하여 실온에서 일주일간 3회 반복 추출하여 추출물을 얻었으며, 이 후 2 내지 3 um 필터 종이를 이용하여 여과하였다. 여과된 작약 에탄올 추출물은 감압 농축기를 사용하여 농축하였다.The peony used in this experiment ( Paeonia lactiflora Pall. ) Was purchased from the Jirisan Herb Goal, which specializes in domestic wild and native herbs in Sancheong - gun, Kyongsang Province. To 5 kg of the shredded peony, 80% (v / v) ethanol was added and extracted three times at room temperature for three times to obtain an extract, which was then filtered using 2 to 3 μm filter paper. The filtered peach ethanol extract was concentrated using a vacuum concentrator.
1-2. 작약 1-2. Peony 분획물의Fraction 제조 Produce
상기 실시예 1-1에서 제조한 작약 추출물을 클로로포름, 에틸 아세트산, 부탄올 및 물 순으로 추가 분획하여 분획물을 얻었으며, 보다 구체적으로는 도 1에 도시한 순서로 순차적 용매 분획을 수행하여 얻었다.The peony extracts prepared in Example 1-1 were further fractionated in the order of chloroform, ethyl acetate, butanol and water to obtain fractions. More specifically, sequential solvent fractions were obtained in the order shown in FIG.
실시예Example 2. 작약 추출물 및 이의 2. Peony extract and its 분획물의Fraction 미백 효과 확인 Confirm whitening effect
실시예 1에서 제조한 작약 추출물 및 작약 분획물의 미백 효과를 확인하기 위하여 티로시나제 활성 억제 효과를 확인하였다. 구체적으로, L-티로신(tyrosine)이 티로시나제에 의하여 산화된 산화물인 DOPA 크롬의 양을 490 nm에서 흡광도 측정에 의해 계산함으로써 티로시나제 활성을 파악하였다. 이를 위해 먼저, 50 mM 인산 나트륨 완충액(pH 7.2), 8 mM L-DOPA(0.36 mM), 버섯 티로시나제 30 U/ml, 상기 작약 추출물 또는 작약 분획물을 포함하여 최종 부피가 500㎕가 되도록 용액을 제조하였으며, 이 후 실온, 475 nm 파장 조건에서 UV-VIS Spectrophotometer(Perkin-Elmer, USA)로 흡광도를 측정하여 티로시나제의 활성을 측정하였다. 그 결과를 작약 추출물 및 작약 분획물 농도와 티로시나제 활성 간의 상관관계를 나타내는 그래프로 나타내었으며, 이를 도 2 내지 6에 각각 표시하였고, 이를 바탕으로 IC50 값을 도출하였으며 이는 표 1에 나타내었다. 실험의 대조군은 알부틴을 사용하였다. The effect of inhibiting tyrosinase activity was confirmed in order to confirm the whitening effect of the peony extract and peony root fraction prepared in Example 1. Specifically, the tyrosinase activity was determined by calculating the amount of DOPA chromium, an oxide oxidized by tyrosine, with L-tyrosine at 490 nm by absorbance measurement. To this end, a solution was prepared so as to have a final volume of 500 μl containing 50 mM sodium phosphate buffer (pH 7.2), 8 mM L-DOPA (0.36 mM), mushroom tyrosinase 30 U / ml, After that, the activity of tyrosinase was measured by measuring the absorbance with UV-VIS Spectrophotometer (Perkin-Elmer, USA) at room temperature and 475 nm wavelength. The results are shown in the graphs showing the correlation between concentrations of peony extract and peony fractions and tyrosinase activity, which are shown in FIGS. 2 to 6, respectively, and IC 50 values are derived from these values. Arbutin was used as a control group.
도 2 내지 도 6 및 표 1에 나타낸 바와 같이, 알부틴(대조군), 작약 클로로포름 분획물, 작약 에틸 아세트산 분획물, 작약 부탄올 분획물 및 작약 물 분획물의 IC50 값은 2.77%, 0.077%, 0.0154%, 0.265% 및 1.28%로 나타났으며, 다시 말해 알부틴 기준으로 작약 에틸 아세트산은 약 180배, 작약 클로로포름 분획물은 약 36배, 작약 부탄올 분획물은 약 10배 및 작약 물 분획물은 약 2배 더 높은 티로시나제 활성 억제 효과를 나타내는 바, 작약 분획물이 모두 우수한 미백 활성 억제 효과를 나타냄을 확인하였다. 특히, 에틸 아세트산 분획물이 가장 뛰어난 티로시나제 활성 억제 효과를 가짐을 확인하였다. As shown in Figs. 2 to 6 and Table 1, the IC 50 values of arbutin (control), fructose chloroform fraction, fructose ethylacetic acid fraction, fructose butanol fraction and fructose fructose fraction were 2.77%, 0.077%, 0.0154%, 0.265% And 1.28%. In other words, the tyrosinase activity inhibition effect was found to be about 180 times higher on the arbutin than on the arbutin, about 36 times higher for the chrysanthemum fraction, about 10 times higher for the peanut butter fraction, , Indicating that the peony fractions showed excellent whitening activity inhibitory effect. In particular, it was confirmed that the ethyl acetic acid fraction had the most excellent tyrosinase activity inhibitory effect.
실시예Example 3. 작약 추출물 및 이의 3. Peony extract and its 분획물의Fraction 항산화 및 노화 방지 효과 확인 Identify antioxidant and anti-aging effects
3-1. 3-1. DPPHDPPH (1,1-(1,1- diphenyl피덴 -2--2- picrylhydrazylpicrylhydrazyl ) 자유 라디칼 Free radical 소거능Scatters 측정 Measure
실시예 1에서 제조한 작약 추출물 및 분획물의 항산화를 통한 노화 개선 효과를 확인하기 위하여 DPPH 자유 라디칼 소거능을 측정하였다. 먼저, 작약 추출물 또는 작약 분획물과 0.1 mM의 DPPH 용액을 혼합하여 암실에서 20 내지 30분 동안 반응시켰다. 이 후 ELISA 마이크로플레이트 리더(Bio-Rad, USA)를 이용하여 517 nm에서 흡광도를 측정하였으며, 이를 바탕으로 IC50 값을 도출하였다. 알부틴과 L-아스코르브산은 대조군으로 사용하였다. 그 결과는 표 2에 나타내었다.DPPH free radical scavenging activity was measured in order to confirm the antioxidative effect of the extracts of the peony root extract prepared in Example 1 and the fractions thereof. First, peony extract or peony fractions and 0.1 mM DPPH solution were mixed and allowed to react in a dark room for 20 to 30 minutes. The absorbance was measured at 517 nm using an ELISA microplate reader (Bio-Rad, USA), and the IC 50 value was calculated based on the absorbance. Arbutin and L-ascorbic acid were used as controls. The results are shown in Table 2.
표 2에 나타낸 바와 같이, 작약 추출물, 작약 클로로포름 분획물, 작약 에틸 아세트산 분획물 및 작약 부탄올 분획물이 0.0094%, 0.0069%, 0.0005% 및 0.0062%의 높은 DPPH 라디칼 소거 활성을 가짐을 확인하였다. 상기 DPPH 라디칼 소거 활성을 대조군인 L-아스코르브산과 비교하면, 작약 추출물은 약 2.5배, 작약 클로로포름 분획물은 약 3.4배, 작약 에틸 아세트산 분획물은 약 45.7배 및 작약 부탄올 분획물은 약 3.8배로 더 높은 DPPH 라디칼 소거 활성을 가짐을 확인할 수 있었다. 다른 대조군인 알부틴과 비교한 경우에도 작약 추출물은 약 5.7배, 작약 클로로포름 분획물은 7.9배, 작약 에틸 아세트산 분획물은 105.7배, 작약 부탄올 분획물은 8.8배 더 높은 DPPH 라디칼 소거 활성을 가짐을 확인하였다. 이는 작약 추출물 및 작약 분획물이 우수한 항산화 활성을 가짐을 나타내며, 특히 작약 에틸 아세트산 분획물이 가장 높은 항산화 활성을 가짐을 나타낸다.As shown in Table 2, it was confirmed that the peony extract, peach chloroform fraction, peanut ethyl acetic acid fraction and peony butanol fraction had high DPPH radical scavenging activity of 0.0094%, 0.0069%, 0.0005% and 0.0062%, respectively. As compared to the control group L-ascorbic acid, the DPPH radical scavenging activity was about 2.5 times higher than that of the control group, the DPPH radical was higher than the DPPH radicals by about 3.4 times, the peanut ethyl acetic acid fraction was about 45.7 times and the peanut fraction was 3.8 times higher It was confirmed that it had an elimination activity. It was also confirmed that DPPH radical scavenging activity was higher than that of arbutin, which is another control group, by about 5.7 times in the peony extract, 7.9 times in the peony chloroform fraction, 105.7 times in the peony root ethyl acetate fraction and 8.8 times in the peony root butanol fraction. This indicates that the peony extract and peony fractions have excellent antioxidative activity, and the peanut ethyl acetic acid fraction has the highest antioxidant activity.
3-3- 2.ABTS(2,2-azino-bis2. ABTS (2,2-azino-bis (3-(3- ethylbenzthiazolineethylbenzthiazoline -6--6- sulfoniculfonic acid) acid) diamdiam -- moniummonium salt) 자유 라디칼 소거능 측정 salt) Free radical scavenging ability measurement
실시예 1에서 제조한 작약 추출물 및 분획물의 항산화를 통한 노화 개선 효과를 확인하기 위하여 ABTS 자유 라디칼 소거능을 측정하였다. 먼저, 7.4 mM의 ABTS 및 2.6 mM 과황산염 칼슘을 혼합한 후 실온 조건의 암실에서 24시간 동안 방치하였다. 이에 의하여 생성된 ABTS 자유 라디칼이 734 nm의 파장에서 흡광도가 0.7가 되도록 에탄올로 희석하였다. 희석된 ABTS 자유 라디칼에 작약 추출물 또는 작약 분획물을 처리한 후, ELISA 마이크로플레이트 리더(Bio-Rad, USA)를 이용하여 734 nm에서 흡광도를 측정하였으며, 이를 바탕으로 IC50 값을 도출하였다. 알부틴과 L-아스코르브산을 대조군으로 사용하였다. 그 결과는 표 3에 나타내었다.The free radical scavenging activity of ABTS was measured in order to confirm the antioxidative effect of the extracts and fractions of peony root extract prepared in Example 1. First, 7.4 mM ABTS and 2.6 mM calcium sulfate were mixed and left in a dark room at room temperature for 24 hours. The resulting ABTS free radical was diluted with ethanol to an absorbance of 0.7 at a wavelength of 734 nm. The diluted ABTS free radicals were treated with peony extract or peony fractions and the absorbance was measured at 734 nm using an ELISA microplate reader (Bio-Rad, USA), and IC 50 values were derived therefrom. Arbutin and L-ascorbic acid were used as controls. The results are shown in Table 3.
표 3에 나타낸 바와 같이, 작약 추출물 및 작약 분획물의 농도 의존적(0.25% 내지 0.0025%의 농도 변화)인 ABTS 자유 라디칼 소거 활성을 확인하였다. 작약 추출물, 작약 클로로포름 분획물, 작약 에틸 아세트산 분획물 및 작약 부탄올 분획물의 IC50 값은 각각 0.038%, 0.012%, 0.002% 및 0.023%임을 확인하였으며, 대조군으로 사용된 아스코르브산과 비교하면 작약 추출물은 약 1.5배, 작약 클로로포름 분획물은 약 5배, 작약 에틸 아세트산 분획물은 약 23.1배 및 작약 부탄올 분획물은 약 2.5배 더 높은 ABTS 라디칼 소거능을 가지는 것을 확인하였고 작약 에틸 아세트산 분획물에서 가장 높은 ABTS 라디칼 소거능이 나타남을 확인하였다. 이는 작약 추출물 및 작약 분획물이 높은 항산화 활성을 가지며, 특히 작약 에틸 아세트산 분획물이 가장 높은 항산화 활성을 가짐을 나타낸다.As shown in Table 3, the ABTS free radical scavenging activity, which is concentration-dependent (concentration change of 0.25% to 0.0025%), of the peony extract and peony fractions was confirmed. The IC 50 values of the peony extract, peanut fraction, ethyl acetate fraction and peony butanol fraction were 0.038%, 0.012%, 0.002% and 0.023%, respectively. Compared with the ascorbic acid used as the control group, , And the ABTS radical scavenging ability was about 5 times higher in the peach chloroform fraction, about 23.1 times in the crude ethyl acetate fraction and about 2.5 times higher in the peach butanol fraction, and the highest ABTS radical scavenging activity was observed in the ethyl acetate fraction . This indicates that the peony extract and peony fractions have a high antioxidative activity, and the peanut ethyl acetic acid fraction has the highest antioxidant activity.
실시예Example 4. 작약 추출물 및 이의 4. Peony extract and its 분획물의Fraction 항균 효과 확인 Confirmation of antibacterial effect
실시예 1에서 제조한 작약 추출물 및 작약 분획물의 항균 효과를 확인하기 위하여 웰 디퓨전 분석(well diffusion assay)을 수행하였다. 먼저, 하기 표 4에 나타낸 균주를 증류수에 현탁하고, 고체 배지에 도말한 후 37℃의 배양기에서 24시간 동안 배양한 것을 실험에 사용하였다. 웰 디퓨전 분석을 위하여 먼저, 고체 배지에서 배양한 상기 균들의 단일 콜로니를 액체 배지에 접종하였으며, 이 후 37℃ 조건 하에 200 rpm으로 교반되는 배양기에서 24시간 동안 배양하였다. 상기 배양액을 1 %만큼 취해 다시 고체 배지로 제조하였으며, 상기 배지를 굳힌 뒤 웰을 뚫어 각 추출물 및 분획물을 2㎕/웰씩 분주하였으며, 37℃에서 배양기(Sanyo Incubator MIR-253)에서 추가로 24시간 배양하고, 그 결과로 확인되는 생육 저해환(clear zone)을 관찰하였다. 그 결과는 표 5에 나타내었다.A well diffusion assay was performed to confirm the antimicrobial effect of the peony extract and the peony extract prepared in Example 1. First, the strains shown in Table 4 below were suspended in distilled water, plated on a solid medium, and cultured in an incubator at 37 ° C for 24 hours. For the well diffusion analysis, first, a single colony of the microorganisms cultured in the solid medium was inoculated into the liquid medium, and then cultured in an incubator stirred at 200 rpm at 37 캜 for 24 hours. Each of the above extracts and fractions was divided into 2 쨉 l / well and incubated at 37 째 C in an incubator (Sanyo Incubator MIR-253) for 24 hours And a clear growth zone was observed as a result. The results are shown in Table 5.
표 5에 나타낸 바와 같이, 작약 에틸 아세트산 분획물, 작약 부탄올 분획물 및 작약 추출물은 황색 포도상구균(S. aureus) 및 표피 포도상구균(S. spidermidis)에 대하여 강한 억제 활성을 확인하였고, 작약 클로로포름 분획물에서는 중간 정도의 억제 활성을 나타냄을 확인하였다. 또한 녹농균(P. aeruginosa)에 대하여 작약 에탈 아세트산 분획물, 작약 부탄올 분획물 및 작약 추출물이 강한 억제 활성을 가짐을 확인하였으며 작약 클로로포름 분획물에서 중간 정도의 억제 활성을 가짐을 확인하였고, 대장균(E. coli)에 대해서는 작약 에틸 아세트산 분획물, 작약 추출물이 가장 강한 억제 활성을 가짐을 확인하였다. 그 중에서도 특히, 상기 모든 균에 대하여 작약 에틸 아세트산 분획물에서 가장 높은 항균 효과를 확인하였다. 상기 결과는 작약 추출물 및 작약 분획물이 높은 항균 효과를 가지며, 이는 상기 물질들이 피부에 사용하는 화장물이나 식품으로 사용하는 데 적합한 물질임을 나타낸다.As shown in Table 5, the fructose ethylacetic acid fractions, peach butanol fractions, and peony extracts showed strong inhibitory activity against S. aureus and S. spidermidis , and in the peach chloroform fraction, , Respectively. In addition, it was confirmed that peach acetic acid fraction, peanut butanol fraction and peony extract had strong inhibitory activity against P. aeruginosa , and it showed moderate inhibitory activity in peanut fraction of chloroform. In E. coli , , The peanut ethyl acetic acid fraction and peony root extract showed the strongest inhibitory activity. Particularly, the highest antimicrobial activity was obtained in the ethyl acetate fraction of Peony root in all the above strains. The results show that the peony extract and peony fractions have a high antimicrobial effect, indicating that these substances are suitable for use as cosmetics or foods for use on the skin.
실시예Example 5. 작약 5. Peony 분획물의Fraction 세포 독성 확인 Cytotoxicity check
실시예 1-2에서 제조한 작약 에틸 아세트산 분획물의 세포 독성을 확인하기 위하여 MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] 분석을 수행하였다. 실험에 사용된 세포는 한국 세포주 은행으로부터 구입한 마우스 멜라노마 세포(melanoma cell)(B16F10)로, 상기 세포를 10% 소태아혈청 및 1% 페니실린 스트렙토마이신이 함유된 DMEM에 현탁하였고, 이 후 이를 3분 동안 25℃에서 1000 rpm으로 원심분리시켰으며, 이 후 이를 배지에 현탁하여 5%의 이산화탄소 배양기에서 24시간 동안 배양한 후에 실험에 사용하였다. 다음으로 상기 세포에서의 세포 독성을 확인하기 위하여 마우스 멜라노마 세포(B16F10)을 9개의 웰 플레이트에 4⁴세포/ml로 배양하였다. 24시간 후 배지를 제거하고 작약 에틸 아세트산 분획물을 농도별(0.1㎕/ml, 0.05㎕/ml, 0.025㎕/ml, 0.013㎕/ml, 0.006㎕/ml 및 0.003㎕/ml)로 처리하였으며 이 후 37℃ 조건하에 5% 이산화탄소 배양기에서 48시간 배양하였다. 이 후 5 mg/ml MTT 시약을 첨가하였으며 5% 이산화탄소 배양기에서 추가적으로 3시간 동안 배양하였다. 이 후 이를 3분 동안 25℃에서 1000 rpm으로 원심분리를 수행하였으며, 웰 바닥에 형성된 포르마잔이 흩어지지 않도록 상등액을 제거하였으며, 상등액이 제거된 웰에 1:1의 DMSO:에탄올을 분주한 후 ELISA 마이크로플레이트 리더(Bio-Rad, USA)를 이용하여 540nm 파장에서 흡광도를 측정하였다. 그 결과는 도 7에 나타내었다. (MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide] analysis was performed to confirm the cytotoxicity of the fractions of ethyl acetic acid prepared in Example 1-2. The cells used in the experiment were suspended in DMEM containing 10% fetal bovine serum and 1% penicillin streptomycin as mouse melanoma cells (B16F10) purchased from Korean Cell Line Bank, After centrifugation at 1000 rpm for 3 minutes at 25 ° C, it was suspended in the medium and incubated in a 5% carbon dioxide incubator for 24 hours before being used in the experiment. Next, mouse melanoma cells (B16F10) were cultured in 9 well plates at 4 cells / ml to confirm cytotoxicity in the cells. After 24 hours, the medium was removed and the fractions of ethyl acetate were treated with concentrations (0.1 μl / ml, 0.05 μl / ml, 0.025 μl / ml, 0.013 μl / ml, 0.006 μl / ml and 0.003 μl / ml) And cultured in a 5% carbon dioxide incubator at 37 캜 for 48 hours. After this, 5 mg / ml MTT reagent was added and incubated for an additional 3 hours in a 5
도 7에 나타낸 바와 같이, 작약 에틸 아세트산 분획물은 높은 세포 생존률을 나타냈다. 이는 작약 에틸 아세트산 분획물이 세포 독성이 없는 안전한 물질임을 나타내며, 동시에 생체적합성을 가지는 바 화장료 및 식품으로 활용하는 데 적합한 물질임을 나타낸다.As shown in Fig. 7, the fragrant ethyl acetic acid fractions showed high cell viability. This indicates that the peanut ethyl acetic acid fraction is a safe substance free from cytotoxicity, and at the same time, it is a biocompatible material suitable for use as a cosmetic and food product.
종합적으로, 본 발명의 작약 추출물 또는 이의 분획물은 티로시나제 활성 억제 효과를 중심으로, DPPH, ABTS 자유 라디칼 소거능, E. coli , S. aureus 등을 포함하는 세균에서의 항균 활성 효과, 즉 현저한 미백, 항산화 또는 항균 효과를 나타낸다. 이에 따라 본 발명은 미백 또는 노화 방지용 화장료 조성물로서 활용될 수 있고, 더 나아가 미백, 항산화 또는 항균과 관련된 건강기능식품, 항균용 조성물, 피부 외용제, 식품 첨가제 등으로 유용하게 활용될 수 있다.Taken together, the peony extracts or fractions thereof of the present invention are effective for inhibiting tyrosinase activity, exhibiting an antimicrobial activity effect in bacterium including DPPH, ABTS free radical scavenging ability, E. coli , S. aureus , Or an antibacterial effect. Accordingly, the present invention can be utilized as a cosmetic composition for preventing whitening or aging, and further useful as a health functional food related to whitening, antioxidant or antibacterial, composition for antibacterial, external preparation for skin, food additive and the like.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
제제예 1. 화장료 제제의 제조Formulation Example 1. Preparation of cosmetic preparation
1. 유연화장수 제조1. Flexible longevity manufacturing
작약 추출물 또는 이의 분획물 1중량%Peony extract or its
1,3-부틸렌글리콜 5.2중량%, 올레일알코올 1.5중량%5.2% by weight of 1,3-butylene glycol, 1.5% by weight of oleyl alcohol,
에탄올 3.2중량%3.2% by weight of ethanol
폴리솔베이트 20 3.2중량%
벤조페논-9 2.0중량%Benzophenone-9 2.0 wt%
카르복실비닐폴리머 1.0중량%, 글리세린 3.5중량%1.0% by weight of a carboxyl vinyl polymer, 3.5% by weight of glycerin,
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 유연화장수를 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare a softening water by a conventional method.
2. 밀크로션 제조2. Milk lotion manufacturing
작약 추출물 또는 이의 분획물 0.1중량%Peach extract or fractions thereof 0.1%
글리세린 5.1중량%Glycerin 5.1 wt%
프로필렌글리콜 4.2중량%Propylene glycol 4.2 wt%
토코페릴아세테이트 3.0중량%3.0% by weight of tocopheryl acetate
유동파라핀 4.6중량%Liquid paraffin 4.6 wt%
트리에탄올아민 1.0중량%1.0% by weight triethanolamine
스쿠알란 3.1중량%Squalane 3.1 wt%
마카다미아너트오일 2.5중량%Macadamia nut oil 2.5 wt%
폴리솔베이트 60 1.6중량%
솔비탄세스퀴롤레이트 1.6중량%1.6% by weight of sorbitan sesquiterate
프로필파라벤 0.6중량%Propyl paraben 0.6 wt%
카르복실비닐폴리머 1.5중량%Carboxyl vinyl polymer 1.5 wt%
미량의 향, 미량의 방부제, 잔량의 정제수를 혼합하여 통상의 방법으로 밀크로션을 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare an milk lotion by a conventional method.
3. 영양크림 제조3. Nutritional cream manufacturing
작약 추출물 또는 이의 분획물 0.5중량%0.5% < tb > < tb >
글리세린 4.0중량%Glycerin 4.0 wt%
바셀린 3.5중량%Vaseline 3.5 wt%
트리에탄올아민 2.1중량%2.1% by weight triethanolamine
유동파라핀 5.3중량%Liquid paraffin 5.3 wt%
스쿠알란 3.0중량%Squalane 3.0 wt%
밀납 2.6중량%Wax 2.6 wt%
토코페릴아세테이트 5.4중량%Tocopheryl acetate 5.4 wt%
폴리솔베이트 60 3.2중량%
카르복실비닐폴리머 1.0중량%Carboxyl vinyl polymer 1.0 wt%
솔비탄세스퀴올레이트 3.1중량%3.1 weight percent sorbitan sesquioleate
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 영양크림을 제조하였다.A minor amount of fragrance, a small amount of preservative, and a remaining amount of purified water were mixed to prepare a nutritional cream by a conventional method.
4. 마사지크림 제조4. Massage cream manufacturing
작약 추출물 또는 이의 분획물 0.5중량%0.5% < tb > < tb >
글리세린 4.0중량%Glycerin 4.0 wt%
바셀린 3.5중량%, 트리에탄올아민 0.5중량%3.5% by weight of petrolatum, 0.5% by weight of triethanolamine,
유동파라핀 24.0중량%Liquid paraffin 24.0 wt%
스쿠알란 3.0중량%, 밀납 2.1중량%Squalane 3.0 wt%, wax 2.1 wt%
토코페릴아세테이트 0.1중량%0.1% by weight of tocopheryl acetate
폴리솔베이트 60 2.4중량%
카르복실비닐폴리머 1.0중량%Carboxyl vinyl polymer 1.0 wt%
솔비탄세스퀴올레이트 2.3중량%2.3 weight% sorbitan sesquioleate
미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 마사지크림을 제조하였다.A minor amount of fragrance, a small amount of preservative and a remaining amount of purified water were mixed to prepare a massage cream by a conventional method.
제제예 2 식품 제제의 제조Formulation Example 2 Preparation of food preparation
1. 건강식품의 제조1. Manufacture of health food
작약 추출물 또는 이의 분획물 100 mgPeony extract or its
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 g 70 g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 g 0.2 g of vitamin B12
비타민 C 10 mgVitamin C 10 mg
비오틴 10 g Biotin 10 g
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 g Folate 50 g
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
2. 건강음료의 제조2. Manufacture of health drinks
작약 추출물 또는 이의 분획물 100 mgPeony extract or its
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 g19.75 g of ferrous lactate
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3 gVitamin B2 0.3 g
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered, sterilized in a sterilized 2 L container, sealed, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
제제예 3. 약학적 제제의 제조Formulation Example 3. Preparation of pharmaceutical preparations
1. 산제의 제조 1. Manufacturing of powder
작약 추출물 또는 이의 분획물 20 mgPeony extract or its
유당 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조할 수 있다.The above components can be mixed and filled in an airtight container to prepare powders.
2. 정제의 제조2. Preparation of tablets
작약 추출물 또는 이의 분획물 10 mgPeony extract or its fractions 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조할 수 있다.After mixing the above components, tablets may be prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of capsules
작약 추출물 또는 이의 분획물 10 mgPeony extract or its fractions 10 mg
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조할 수 있다.The above components may be mixed and filled in a gelatin capsule according to a conventional method for preparing a capsule, thereby preparing a capsule.
4. 주사제의 제조4. Preparation of injections
작약 추출물 또는 이의 분획물 10 mgPeony extract or its fractions 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO42H2O 26 mgNa 2 HPO 4 2H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ml) 상기의 성분 함량으로 제조할 수 있다.(2 ml) per 1 ampoule according to the usual injection preparation method.
5. 액제의 제조5. Manufacture of liquids
작약 추출물 또는 이의 분획물 20 mgPeony extract or its
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고, 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 다시 정제수를 가한다. 전체를 정제수로 가한 액제의 약을 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 최종적으로 액제를 제조할 수 있다.Each component is added to and dissolved in purified water according to a conventional liquid preparation method, and the lemon flavor is added in an appropriate amount, then the above components are mixed, and then purified water is added. The total amount of the liquid agent added to the purified water is adjusted to 100 ml, and the liquid agent can be finally prepared by filling it in a brown bottle and sterilizing it.
Claims (10)
A cosmetic composition for skin whitening or antiaging treatment comprising peony extract or fraction thereof as an active ingredient.
상기 작약 추출물은 작약 줄기 추출물인 것을 특징으로 하는, 화장료 조성물.
The method according to claim 1,
Wherein the peony extract is a peony root extract.
상기 작약 추출물은 물, C1-C4 알코올 또는 이의 혼합용매로 추출되는 것을 특징으로 하는, 화장료 조성물.
The method according to claim 1,
The cosmetic composition according to claim 1 , wherein the crude extract is extracted with water, a C 1 -C 4 alcohol or a mixed solvent thereof.
상기 분획물은 클로로포름, 에틸 아세트산, 부탄올 및 물로 이루어진 군으로부터 선택된 어느 하나 이상의 용매로 분획한 분획물인 것을 특징으로 하는, 화장료 조성물.
The method according to claim 1,
Wherein the fraction is a fraction obtained by fractionating with at least one solvent selected from the group consisting of chloroform, ethyl acetic acid, butanol and water.
상기 작약 추출물 또는 이의 분획물은 전체 화장료 조성물에 대하여 0.001 내지 60 중량%로 포함되는 것을 특징으로 하는, 화장료 조성물.
The method according to claim 1,
The cosmetic composition according to claim 1, wherein the peony extract or the fraction thereof is contained in an amount of 0.001 to 60% by weight based on the whole cosmetic composition.
A health functional food composition for improving skin condition comprising peanut extract or fraction thereof as an active ingredient.
상기 피부 상태 개선용은 미백 또는 항산화용인 것을 특징으로 하는, 건강기능식품 조성물.
The method according to claim 6,
Wherein the skin condition improving agent is for whitening or antioxidant.
An antimicrobial composition comprising a peony root extract or a fraction thereof as an active ingredient.
A composition for external application for skin for antimicrobial use comprising a peony extract or a fraction thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160182816A KR20180077927A (en) | 2016-12-29 | 2016-12-29 | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160182816A KR20180077927A (en) | 2016-12-29 | 2016-12-29 | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180077927A true KR20180077927A (en) | 2018-07-09 |
Family
ID=62919648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160182816A Ceased KR20180077927A (en) | 2016-12-29 | 2016-12-29 | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180077927A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101943346B1 (en) * | 2018-11-16 | 2019-01-29 | 주식회사 아리바이오 | Paeoniari Oil manufacturing method |
KR20200016101A (en) * | 2018-08-06 | 2020-02-14 | 지에스칼텍스 주식회사 | Method for producing the extracts of natural material using ethyl lactate |
CN111388367A (en) * | 2020-03-25 | 2020-07-10 | 江南大学 | A kind of composition and preparation method of multi-target inhibiting melanin and its application in cosmetics |
KR102159826B1 (en) | 2019-12-09 | 2020-09-24 | 주식회사 아미코스메틱 | An antimicrobial composition comprising a covenant extract cultivated with desalination mineral lava seawater and method thereof |
KR20210058046A (en) * | 2019-11-13 | 2021-05-24 | 주식회사 라비오 | Anti-inflamatory composition comprising fermented ginseng using mixed strain and preparation method thereof |
CN113433256A (en) * | 2021-07-05 | 2021-09-24 | 浙江工业大学 | Screening method of whitening active ingredients in traditional Chinese medicine |
-
2016
- 2016-12-29 KR KR1020160182816A patent/KR20180077927A/en not_active Ceased
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200016101A (en) * | 2018-08-06 | 2020-02-14 | 지에스칼텍스 주식회사 | Method for producing the extracts of natural material using ethyl lactate |
KR101943346B1 (en) * | 2018-11-16 | 2019-01-29 | 주식회사 아리바이오 | Paeoniari Oil manufacturing method |
KR20210058046A (en) * | 2019-11-13 | 2021-05-24 | 주식회사 라비오 | Anti-inflamatory composition comprising fermented ginseng using mixed strain and preparation method thereof |
KR102159826B1 (en) | 2019-12-09 | 2020-09-24 | 주식회사 아미코스메틱 | An antimicrobial composition comprising a covenant extract cultivated with desalination mineral lava seawater and method thereof |
CN111388367A (en) * | 2020-03-25 | 2020-07-10 | 江南大学 | A kind of composition and preparation method of multi-target inhibiting melanin and its application in cosmetics |
CN111388367B (en) * | 2020-03-25 | 2021-09-24 | 江南大学 | A kind of composition and preparation method of multi-target inhibiting melanin and its application in cosmetics |
CN113433256A (en) * | 2021-07-05 | 2021-09-24 | 浙江工业大学 | Screening method of whitening active ingredients in traditional Chinese medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180077927A (en) | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof | |
KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
KR102299277B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora edulis | |
WO2011043212A1 (en) | Ceramide production enhancer and moisturizing agent | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
KR102201305B1 (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
KR102275055B1 (en) | Composition comprising scutellaria alpina extract | |
KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
KR102224313B1 (en) | Composition for skin whitening comprising scutellaria alpina extract | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR20230166330A (en) | Composition for inhibiting muscle contraction comprising extracts of herbal mixtures as an active ingredient | |
KR102604373B1 (en) | Improvement composition for Hot flash comprising the extract of Salvia miltiorrhiza as an active ingredient | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR102047461B1 (en) | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof | |
KR102777268B1 (en) | Cosmethic composition for skin whitening containing essential oil of Siegesbeckia glabrescens Makino flower | |
KR102200013B1 (en) | Composition comprising artemisia umbelliformis extract | |
KR20160081211A (en) | Composition for improving skin condition comprising extract of colored barley | |
KR102274305B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora laurifolia | |
KR102544546B1 (en) | Composition for anti-obesity containing mixture of plant leaf extract including pine needle as effective component | |
KR102475143B1 (en) | Composition for Skin Regeneration Comprising Extract of Vanilla Bean | |
KR102502445B1 (en) | Composition for preventing or treating obesity and/or metabolic syndrome comprising Albizia julibrissin extracts | |
JP6204019B2 (en) | CGI-58 expression promoter | |
KR101767192B1 (en) | A composition having anti-bacterial activity comprising 16alpha-hydroxy-17-isovaleroyloxy-ent-kauran-19-oic acid as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20161229 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180309 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180625 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20181112 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20180625 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20180309 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |